INCYTE CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INCYTE CORPORATION (INCY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $64.13 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-04-28
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $64.13M, a 5.16% increase year-over-year.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $62.16M.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $61.60M, a 20.95% decline year-over-year.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $64.61M, a 14.08% increase year-over-year.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $249.35M, a 6.28% decline from fiscal 2024.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $266.06M, a 22.90% increase from fiscal 2023.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $216.47M, a 14.12% increase from fiscal 2022.
- INCYTE CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $189.69M, a 2.46% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-03-31 | $64.13M 10-Q · filed 2026-04-28 | $126.28M derived: sum of 2 quarters · filed 2026-04-28 | $187.88M derived: sum of 3 quarters · filed 2026-04-28 | $252.49M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $62.16M derived: 10-K 12 month − 3 quarters · filed 2026-02-10 | $123.75M derived: sum of 2 quarters · filed 2026-02-10 | $188.36M derived: sum of 3 quarters · filed 2026-02-10 | $249.35M 10-K · filed 2026-02-10 |
| 2025-09-30 | $61.60M 10-Q · filed 2025-10-28 | $126.21M derived: sum of 2 quarters · filed 2025-10-28 | $187.19M derived: sum of 3 quarters · filed 2026-04-28 | |
| 2025-06-30 | $64.61M 10-Q · filed 2025-10-28 | $125.59M derived: sum of 2 quarters · filed 2026-04-28 | ||
| 2025-03-31 | $60.98M 10-Q · filed 2026-04-28 | |||
| 2024-12-31 | $266.06M 10-K · filed 2026-02-10 | |||
| 2024-09-30 | $77.92M 10-Q · filed 2025-10-28 | $134.56M derived: sum of 2 quarters · filed 2025-10-28 | $194.34M derived: sum of 3 quarters · filed 2025-10-28 | |
| 2024-06-30 | $56.64M 10-Q · filed 2025-10-28 | $116.42M derived: sum of 2 quarters · filed 2025-10-28 | ||
| 2024-03-31 | $59.78M 10-Q · filed 2025-10-28 | |||
| 2023-12-31 | $216.47M 10-K · filed 2026-02-10 | |||
| 2023-09-30 | $48.00M 10-Q · filed 2024-10-29 | $102.93M derived: sum of 2 quarters · filed 2024-10-29 | $156.49M derived: sum of 3 quarters · filed 2024-10-29 | |
| 2023-06-30 | $54.93M 10-Q · filed 2024-10-29 | $108.49M derived: sum of 2 quarters · filed 2024-10-29 | ||
| 2023-03-31 | $53.56M 10-Q · filed 2024-10-29 | |||
| 2022-12-31 | $189.69M 10-K · filed 2025-02-10 | |||
| 2022-09-30 | $45.66M 10-Q · filed 2023-10-31 | $92.16M derived: sum of 2 quarters · filed 2023-10-31 | $136.47M derived: sum of 3 quarters · filed 2023-10-31 | |
| 2022-06-30 | $46.50M 10-Q · filed 2023-10-31 | $90.82M derived: sum of 2 quarters · filed 2023-10-31 | ||
| 2022-03-31 | $44.32M 10-Q · filed 2023-10-31 | |||
| 2021-12-31 | $185.13M 10-K · filed 2024-02-13 | |||
| 2021-09-30 | $43.31M 10-Q · filed 2022-11-01 | $88.67M derived: sum of 2 quarters · filed 2022-11-01 | $136.57M derived: sum of 3 quarters · filed 2022-11-01 | |
| 2021-06-30 | $45.35M 10-Q · filed 2022-11-01 | $93.25M derived: sum of 2 quarters · filed 2022-11-01 | ||
| 2021-03-31 | $47.90M 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | $178.53M 10-K · filed 2023-02-07 | |||
| 2020-09-30 | $43.97M 10-Q · filed 2021-11-02 | $90.38M derived: sum of 2 quarters · filed 2021-11-02 | $133.13M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $46.41M 10-Q · filed 2021-11-02 | $89.16M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $42.76M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $167.03M 10-K · filed 2022-02-08 | |||
| 2019-09-30 | $43.47M 10-Q · filed 2020-11-05 | $84.18M derived: sum of 2 quarters · filed 2020-11-05 | $124.87M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $40.71M 10-Q · filed 2020-11-05 | $81.40M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $40.69M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $148.27M 10-K · filed 2021-02-09 | |||
| 2018-09-30 | $38.00M 10-Q · filed 2019-10-29 | $74.61M derived: sum of 2 quarters · filed 2019-10-29 | $110.83M derived: sum of 3 quarters · filed 2019-10-29 | |
| 2018-06-30 | $36.60M 10-Q · filed 2019-10-29 | $72.83M derived: sum of 2 quarters · filed 2019-10-29 | ||
| 2018-03-31 | $36.22M 10-Q · filed 2019-10-29 | |||
| 2017-12-31 | $133.06M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $96.20M 10-K · filed 2019-02-14 | |||
| 2015-12-31 | $69.87M 10-K · filed 2018-02-15 | |||
| 2014-12-31 | $62.16M 10-K · filed 2017-02-14 | |||
| 2013-12-31 | $38.40M 10-K · filed 2016-02-12 | |||
| 2012-12-31 | $38.49M 10-K · filed 2015-02-17 | |||
| 2011-12-31 | $28.98M 10-K · filed 2014-02-21 | |||
| 2010-12-31 | $14.86M 10-K · filed 2013-02-21 | |||
| 2009-12-31 | $9.98M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |